Journal of Molecular and Cellular Cardiology
Volume 47, Issue 6 , Pages 835-845 , December 2009

Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches

  • Ning Li

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Jun-Yan Liu

      Affiliations

    • Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
    • ,
  • Valeriy Timofeyev

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Hong Qiu

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Sung Hee Hwang

      Affiliations

    • Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
    • ,
  • Dipika Tuteja

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Ling Lu

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Jun Yang

      Affiliations

    • Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
    • ,
  • Hideki Mochida

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Reginald Low

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • ,
  • Bruce D. Hammock

      Affiliations

    • Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
    • ,
  • Nipavan Chiamvimonvat

      Affiliations

    • Division of Cardiovascular Medicine, University of California, Davis, Davis, CA, USA
    • Department of Veterans Affairs, Northern California Health Care System, Mather, CA, USA
    • Corresponding Author InformationCorresponding author. Division of Cardiovascular Medicine, University of California, Davis, One Shields Avenue, GBSF 6315, Davis, CA 95616, USA. Fax: +1 530 752 3264.

Received 23 July 2009 ,Accepted 8 August 2009.

References 

  1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 Feb 6;115(5):e69–171
  2. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003;65:45–79
  3. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad Sci. U. S. A. 1999 Aug 3;96(16):8849–8854
  4. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 2002 May 1;63(9):1599–1608
  5. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 2005;45:311–333
  6. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad Sci. U. S. A. 2006 Dec 5;103(49):18733–18738
  7. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 2000 Nov 24;87(11):992–998
  8. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch. Biochem. Biophys. 1996 Jun 1;330(1):87–96
  9. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 2007 Mar;292(3):C996–1012
  10. Campbell WB. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol. Sci. 2000 Apr;21(4):125–127
  11. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999 Aug 20;285(5431):1276–1279
  12. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 2007 Aug 9;50(16):3825–3840
  13. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genomics. 2004 Feb 13;16(3):349–360
  14. Dawn B, Guo Y, Rezazadeh A, Huang Y, Stein AB, Hunt G, et al. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ. Res. 2006 Apr 28;98(8):1098–1105
  15. Huang B, El-Sherif T, Gidh-Jain M, Qin D, El-Sherif N. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J. Cardiovasc. Electrophysiol. 2001 Feb;12(2):218–225
  16. Xu Y, Zhang Z, Timofeyev V, Sharma D, Xu D, Tuteja D, et al. The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice. J. Physiol. 2005 Feb 1;562(Pt 3):745–758
  17. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers. Arch. 1981;391(2):85–100
  18. Berul CI, Aronovitz MJ, Wang PJ, Mendelsohn ME. In vivo cardiac electrophysiology studies in the mouse. Circulation. 1996 Nov 15;94(10):2641–2648
  19. Zhang Z, He Y, Tuteja D, Xu D, Timofeyev V, Zhang Q, et al. Functional roles of Cav1.3 (α1D) calcium channels in atria. Insights gained from gene-targeted null mutant mice. Circulation. 2005 Sep 27;112(13):1936–1944
  20. Wixtrom RN, Silva MH. Hammock BD. Cytosolic epoxide hydrolase in human placenta. Placenta. 1988 Sep-Oct;9(5):559–563
  21. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 2005 Feb;11(2):214–222
  22. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ. Res. 2004 Sep 3;95(5):506–514
  23. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin. Exp. Pharmacol. Physiol. 2000 Nov;27(11):855–865
  24. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 1996 Nov;7(11):2364–2370
  25. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2006 Aug;291(2):H537–H542
  26. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004 Oct 12;110(15):2132–2136
  27. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 2006 May 15;15(10):1640–1649
  28. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J. Biol. Chem. 1999 Sep 24;274(39):27339–27342
  29. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999 Nov 22;18(49):6867–6874
  30. Rothwarf DM, Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE. 1999 Oct 26;1999(5):RE1
  31. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 2004 Jan;43(1):55–90
  32. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc. Res. 1998 Feb;37(2):324–334
  33. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 2006 Aug 18;99(4):442–450
  34. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 2008 Nov;295(5):H2128–H2134
  35. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 2008 Jun;294(6):H2838–H2844
  36. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 2005 Jul 12;102(28):9772–9777

PII: S0022-2828(09)00330-7

doi: 10.1016/j.yjmcc.2009.08.017

Journal of Molecular and Cellular Cardiology
Volume 47, Issue 6 , Pages 835-845 , December 2009

Article Tools

* Image Usage & Resolution